ACC 2021 In the PARADISE-MI trial, treatment with sacubitril/valsartan resulted in a non-significant 10% decrease in the primary outcome compared to ramipril in high risk acute MI patients.
ACC 2021 A short summary of the PARADISE-MI trial with sacubitril/valsartan compared to rampitril in MI patients is provided by prof. Pfeffer.
CV benefits of rosuvastatin, compared with placebo, are sustained or enhanced even after stopping therapy in individuals without CVD but at intermediate risk for CV events.
In the FIGARO-DKD phase 3 trial, the nonsteroidal MRA finerenone reduced the primary endpoint, a composite of CV death and non-fatal CV events, compared to placebo in patients with CKD and T2DM.
Prof. Januzzi talks about the biology of natriuretic peptides and discusses their performance in patients with kidney disfunction for diagnosis and prognosis of HF.
Experts in dialogue The approach of upfront combination therapy in very-high risk patients is easier for physicians and a big win for patients, according to prof. Stroes and prof. Masana.
The European Heart Rhythm Association has released the 2021 update of the practical guide on the use of non-vitamin K antagonist oral anticoagulants (NOACs) in AF patients.
MI patients with atypical symptoms had a lower chance of receiving an emergency dispatch, and higher 30-day mortality compared to MI patients with chest pain. Breathing problems was the most common atypical symptom.
This systematic review for the US Preventive Services Task Force provides an overview of benefits and harms of screening for hypertension in adults and on the accuracy of screening and confirmatory BP measurements.
Based on a recent position paper endorsed by the International Lipid Expert Panel, prof. Banach discusses pathways of optimal lipid-lowering therapy in very-high and extremely-high risk patients.
This analysis in a community-based cohort showed that elevated carotid intima-media thickness and interadventitial diameter and lower carotid distensibility were associated with increased risk of incident dementia.
Relative risk reductions by dapagliflozin on CV outcomes were irrespective of baseline eGFR and albuminuria status in T2DM patients who had or were at risk of ASCV, shown in a secondary analysis of DECLARE-TIMI 58.